VOLITIONRX LTD (VNRX): Entry into a Material Definitive Agreement
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 vnrx_ex101.htm FORM OF SECURITIES PURCHASE AGREEMENT vnrx_ex101.htm EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 7, 2026, between VolitionRx Limited, a Delaware corporation (the “ Company ”), and
How this was made
The 30-second read
Why it matters
A securities purchase agreement typically precedes issuance of common stock and warrants; this can affect valuation through dilution and changes to capital structure, while also potentially extending cash runway.
Market read
This is a primary disclosure of a financing agreement structure (stock + immediately exercisable warrants), which can drive trading via dilution/overhang expectations.
What to watch
Traders should verify the final agreement economics (subscription amount, pricing, share/warrant counts, closing conditions, and any beneficial ownership limits) because those determine dilution magnitude and near-term overhang.
Background
The article is an SEC Form 8-K reporting Item 1.01: entry into a material definitive agreement, with Exhibit 10.1 providing the form of a securities purchase agreement dated June 7, 2026.
Ticker impact
VolitionRx entered a material definitive securities purchase agreement, triggering a new equity/warrant issuance structure disclosed in the 8-K exhibit.
Near-term pressure possible from dilution/overhang; direction depends on deal size/terms not shown in the excerpt.
This is a primary SEC 8-K disclosure of a material definitive agreement; however, the provided text is largely boilerplate and does not include key economic terms (e.g., gross proceeds, share count, pricing), limiting precision on magnitude.
Market effects
Biopharma/small-cap financing via warrant structures can increase sector-wide sensitivity to dilution and capital runway narratives.
Primarily US small-cap/biotech investor base; limited broader regional spillover expected.
Low—this is company-specific SEC financing disclosure with no stated cross-border transaction.
Counterpoint
If the financing terms are favorable (e.g., tight discount, limited warrant coverage, or strategic investors), the market may re-rate the stock despite dilution risk.
Key entities
- companyVolitionRx Limited
Issuer entering the securities purchase agreement disclosed in the 8-K (Exhibit 10.1).
- counterpartiesPurchasers (unnamed in excerpt)
Investors identified on signature pages; their identity and terms can influence perceived deal quality.
- security_termsCommon Warrants
Warrants exercisable immediately with a five-year term, as defined in the exhibit excerpt.
